Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYBR CyberCare the new look of healthcare -- Ignore unavailable to you. Want to Upgrade?

To: sommovigo who wrote (2052)	6/1/2000 1:11:00 AM
From: Kevin Podsiadlik	Read Replies (1) \| Respond to of 3392

That is weird... Either Herb has really good contacts at the FDA, or he's an awfully good guesser, or... could it be that the notification mentioned in the PR was not, as you assumed, the first such notice given to CYBR of the 200's general-purpose status? For example, the notification might have been along the lines of: "You are hereby notified that you are forbidden from issuing any further press releases regarding the EHC 400 product, until such time as a determination of its approvability has been made. This sanction does not apply to the EHC 200, which, as you know, is classified as a general-purpose device and therefore not subject to FDA approval." Last Friday's PR would be a technically accurate, if rather incomplete, reporting of such a notification.